{"filing":{"accession_number":"0001493152-26-024872","cik":"0001873835","ticker":"IMMX","company_name":"Immix Biopharma, Inc.","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1873835/000149315226024872/form8-k.htm"},"events":[{"id":9535,"run_id":8365,"accession_number":"0001493152-26-024872","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses an underwritten public offering of 16,778,524 shares of common stock at $8.94 per share, with expected net proceeds of approximately $140.65 million. This is a material dilutive equity issuance that would significantly affect existing shareholders' ownership percentages and is disclosed under Item 8.01 (Other Events) with an underwriting agreement and prospectus supplement filed pursuant to Rule 424(b)(5).","company_name":"Immix Biopharma, Inc.","ticker":"IMMX","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":1193,"accession_number":"0001493152-26-024872","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses an underwritten public offering of 16,778,524 shares of common stock at $8.94 per share, with expected net proceeds of approximately $140.65 million. This is a material dilutive equity issuance that would significantly affect existing shareholders' ownership percentages and is disclosed under Item 8.01 (Other Events) with an underwriting agreement and prospectus supplement filed pursuant to Rule 424(b)(5).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:02:47.055008+00:00","company_name":"Immix Biopharma, Inc.","ticker":"IMMX","filing_date":"2026-05-21"}]}